SGLT2 Inhibitors Nudge Hemoglobin: More Blood or Less Water?

Key Takeaway

Across 85 randomized trials involving 70,543 patients, SGLT2 inhibitors raised hemoglobin by about 0.60 g/dL and hematocrit by about 2.36% more than control treatments. The rise came with higher erythropoietin and lower transferrin saturation, which suggests the body is making more red blood cells. Whether this modest bump changes how patients feel or fare is still unknown.

The Lab Report That Looked Too Good

Picture a 64-year-old man with type 2 diabetes and chronic kidney disease, 3 months into a new prescription for empagliflozin. For years his hemoglobin has hovered around 12.1 g/dL. Today it reads 12.8. He leans forward and asks the obvious question: is my anemia getting better? His physician hesitates, because the honest answer depends on whether he now has more blood, or simply less water carrying it.

That question has followed the SGLT2 inhibitors since their earliest trials. The class includes dapagliflozin, empagliflozin and canagliflozin. These drugs were built to make the kidneys spill sugar into the urine. To everyone’s surprise, they went on to protect the heart and kidneys far beyond what blood sugar control alone could explain. Along the way, a small quirk kept turning up: blood counts crept upward. Early on, most clinicians wrote this off as the drugs’ mild water-pill…